Walgreens Boots Alliance (NASDAQ:WBA) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Friday, February 2nd.
WBA has been the subject of a number of other research reports. Pivotal Research reduced their target price on Walgreens Boots Alliance from $85.00 to $73.00 and set a “hold” rating for the company in a report on Tuesday, October 24th. Needham & Company LLC reaffirmed a “buy” rating and set a $94.00 price target on shares of Walgreens Boots Alliance in a research note on Thursday, October 12th. Deutsche Bank began coverage on Walgreens Boots Alliance in a research note on Monday, December 4th. They set a “hold” rating and a $78.00 price target for the company. Vetr raised Walgreens Boots Alliance from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 12th. Finally, Zacks Investment Research upgraded Walgreens Boots Alliance from a “hold” rating to a “buy” rating and set a $82.00 price objective for the company in a research report on Saturday, January 13th. Eleven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Walgreens Boots Alliance has an average rating of “Buy” and a consensus target price of $85.53.
Walgreens Boots Alliance (NASDAQ:WBA) opened at $68.46 on Friday. The company has a current ratio of 0.96, a quick ratio of 0.47 and a debt-to-equity ratio of 0.48. The stock has a market cap of $67,821.20, a P/E ratio of 12.97, a PEG ratio of 1.16 and a beta of 1.18. Walgreens Boots Alliance has a 1 year low of $63.82 and a 1 year high of $88.00.
Walgreens Boots Alliance (NASDAQ:WBA) last issued its quarterly earnings results on Thursday, January 4th. The pharmacy operator reported $1.28 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.27 by $0.01. Walgreens Boots Alliance had a return on equity of 19.15% and a net margin of 3.19%. The firm had revenue of $30.74 billion during the quarter, compared to the consensus estimate of $30.39 billion. During the same period last year, the company earned $1.10 earnings per share. The company’s revenue for the quarter was up 7.9% on a year-over-year basis. research analysts predict that Walgreens Boots Alliance will post 5.71 EPS for the current year.
Walgreens Boots Alliance declared that its board has approved a stock repurchase program on Wednesday, October 25th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the pharmacy operator to purchase shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.
In other Walgreens Boots Alliance news, insider Stefano Pessina bought 98,858 shares of the business’s stock in a transaction on Monday, January 15th. The shares were bought at an average cost of $76.07 per share, with a total value of $7,520,128.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 14.80% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Pathstone Family Office LLC grew its stake in Walgreens Boots Alliance by 226.6% during the 2nd quarter. Pathstone Family Office LLC now owns 1,179 shares of the pharmacy operator’s stock worth $1,969,000 after buying an additional 818 shares during the last quarter. Hudock Capital Group LLC grew its stake in Walgreens Boots Alliance by 0.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,306 shares of the pharmacy operator’s stock worth $102,000 after buying an additional 6 shares during the last quarter. Westside Investment Management Inc. grew its stake in Walgreens Boots Alliance by 10.4% during the 2nd quarter. Westside Investment Management Inc. now owns 1,325 shares of the pharmacy operator’s stock worth $102,000 after buying an additional 125 shares during the last quarter. Zions Bancorporation grew its stake in Walgreens Boots Alliance by 983.3% during the 3rd quarter. Zions Bancorporation now owns 1,365 shares of the pharmacy operator’s stock worth $105,000 after buying an additional 1,239 shares during the last quarter. Finally, Bristlecone Advisors LLC bought a new position in Walgreens Boots Alliance during the 3rd quarter worth $135,000. Institutional investors and hedge funds own 61.57% of the company’s stock.
WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/13/valuengine-downgrades-walgreens-boots-alliance-wba-to-hold.html.
Walgreens Boots Alliance Company Profile
Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.